Crispr Therapeutics' current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles. Click ...

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

Shares of CRISPR Therapeutics CRSP have risen 14% over the past month, likely driven by encouraging results from the first ...

In a global first for Africa, UCT is participating in a clinical trial to reprogramme genes and halt hereditary angioedema.

SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that the first patient has been dosed in ...

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.

This video explores how CRISPR, the groundbreaking gene-editing technology, is being used in clinical trials to partially restore sight in people with inherited retinal diseases. We break down the ...

The world’s first patient to successfully receive a CRISPR gene-editing treatment was discharged from Children’s Hospital of Philadelphia on June 2, ABC News reported.  KJ Muldoon, a 10-month-old who ...

TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal ...

Using CRISPR to correct the mutations behind polycystic kidney disease could counter some of the damage the condition causes ...